MIRA INFORM REPORT

Report Date :

04.12.2007

IDENTIFICATION DETAILS

Name :	HIZAT PHARMACEUTICAL INDUSTRIES PVT LTD

Registered Office :	170-Industrial Estate, Jamrud Road, Peshawar,

Country :	Pakistan

Date of Incorporation :	1991

Com. Reg. No.:	0024474

Legal Form :	Private Limited Company

Line of Business :	Manufacture & Marketing of Pharmaceutical Products

RATING & COMMENTS

MIRA’s Rating :

RATING		STATUS	PROPOSED CREDIT LINE
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory

Status :	Satisfactory

Payment Behaviour :	No Complaints

Litigation :	Clear

COMPANY NAME

HIZAT PHARMACEUTICAL INDUSTRIES (PVT.) LIMITED

Address

Registered Address & Factory

170-Industrial Estate, Jamrud Road, Peshawar, Pakistan

Tel 92 (91) 2564983, 5814905

Fax 92 (91) 2216589

Email ---

Short Description Of Business

Nature of Business Manufacture & Marketing of Pharmaceutical Products

Year Established 1991

Registration # 0024474

Branches

In Karachi & Lahore

Auditors

M/s Munawar Associates

(Chartered Accountants)

2^nd Floor, Kothalia Mansion, 2 Mcleod Road, Lahore, Pakistan

Legal Status

Subject Company was established as a Private Limited Company in 1991

Authorized Capital	Rs. 4,000,000/- divided into 40,000 shares of Rs. 100/- each
Issued & Paid up Capital	Rs. 2,294,500/- divided into 22,945 shares of Rs. 100/- each

Details of Directors

Names

Nationality

Address

Occupation

Designation

Mr. Ali Haider

Mr. Muhammad Tahir

Mr. Noor Haider

Mr. Muhammad Iqbal

Mr. Zarafat Sair

Pakistani

Shams Medicine Market, Bajouri Gate, Peshawar

Business

Chief Executive

Director

Shareholders

Names

Mr. Ali Haider

Mr. Muhammad Tahir

Mr. Noor Haider

Mr. Muhammad Iqbal

Mr. Zarafat Sair

Associates

Subsidiary

None

Associated Companies

Zasco Pharma Sevices, Pakistan.

Products

ALCIT, CIPROZAT, CLORAN-S, CROTAMITON, EMILON, ENTROXONE, FENIM, FUNGESTIN, FURAZOLINE, HICARMA, HICEF, HICOT, HIFLUZOLE, HIGESIC, HIZALGIN, HIZEMOX, HIZEXIN, HIZILIX, HIZOFEN, HIZOGEL, HIZOPEN, HIZOVIT, HIZYME, HUGON, ICHTYOL, KYKIL, LANDAXAN, LEUCONIL, MEFNACIN, MEFUDOL, METENZOLE, METRAFED, OPRAZOLE, PANREST, PARACETAMOL, PENICILLIN V, POMEX, PONEC, PROMETHAZINE, PULCORIDE, RENESED, RUPIROX, SURFADINE, THEOPHYLLIN, TRISULFA, VERPEL, VITAFFEROL, YANIL, ZAPEX, ZARSINE, ZOROXIN, TRADOL

Number of Employees

Annual Production Volume

The capacity and production of the company’s plant is indeterminable as it is multi-product and involves varying processes of manufacturing.

Annual Sales Volume

Year In Pak Rupees

2006 35,000,000/- (Estimated)

Trade Suppliers (Foreign)

(1) JRS PHARMA GMBH & CO, GERMANY.

(2) SHANGHAI SIPI PHARMACEUTICAL CO. LTD, CHINA.

Distributors

Mainly in Lahore, Peshawar & Mardan

Exporting Countries

No export activity at present

Bankers

PICIC Commercial Bank Ltd, B-1 Phase V, Hayatabad, Peshawar, Pakistan.

Memberships

Pakistan Pharmaceutical Manufacturers Associations.(PPMA)

Sarhad Chamber of Commerce & Industry.(SCCI)

Foreign Exchange Rates

Currency	Unit	Pakistani Rupee
US Dollar	1	Rs. 61.45
UK Pound	1	Rs. 126.55
Euro	1	Rs. 89.90

Comments

Subject Company was established in 1991 and is engaged in manufacturing & marketing of Pharmaceutical Products. Market reputation is satisfactory. Trade relations are reported as fair. The Company can be considered for normal business dealings at usual trade terms and conditions.

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
NR		In view of the lack of information, we have no basis upon which to recommend credit dealings	No Rating

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions